Novartis offers 2 options for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Click on GLEEVEC.com to continue to learn about GLEEVEC® (imatinib mesylate) or click the box below to learn more about another option.
FIND OUT ABOUT ANOTHER Ph+ CML TREATMENT OPTION
that is available for newly diagnosed patients in the chronic phase or patients who are no longer responding or are intolerant to GLEEVEC.